CEO COMMENTS
Kristina Torfgård comments Q3 report 2024
“The important progress we made during the quarter, especially on our three most advanced projects mesdopetam, pirepemat and IRL757, has further strengthened our position, where the success of our projects bringing us closer to new and better treatments for people with Parkinson’s disease.”
LATEST REPORTS
IRLAB to present at ABGSC Investor Days on December 4, 2024
Gothenburg, Sweden, November 29, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the ABGSC Investor Days on Wednesday, December 4, 2024, in Stockholm, Sweden.
Read More >
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >FINANCIAL CALENDAR
NEXT
July 10, 2024
Interim Report January – June 2024